Anti-claudin 18.2 antibody and its uses
Anti-claudin 18.2 antibodies, including murine, chimeric, and humanized variants, provide a targeted therapeutic approach for cancers by binding to claudin 18.2, enhancing tumor inhibition efficacy through efficient endocytosis.
Patent Information
- Application Number
- JP2021557129
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-01
- Filing Date
- 2020-03-31
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2040-03-31
AI Technical Summary
Current therapies lack effective targets for treating various types of cancer, particularly those that exploit the differential expression of claudin 18.2, which is often overexpressed in gastric cancer and other tumors.
Development of anti-claudin 18.2 antibodies, including murine, chimeric, and humanized antibodies, with specific variable regions and constant regions, designed to target and bind to claudin 18.2, potentially used in antibody-drug conjugates for targeted cancer therapy.
The anti-claudin 18.2 antibodies demonstrate high affinity and efficient endocytosis, offering potent tumor inhibition and broad pharmaceutical applications for treating claudin 18.2-positive cancers.
Smart Images

Figure 0007592022000020 
Figure 0007592022000021 
Figure 0007592022000022
Abstract
Description
[Technical field]
[0001] This application claims priority to Chinese Patent Application No. 201910257853.6, filed on April 1, 2019, the entire contents of which are incorporated herein by reference.
[0002] The present disclosure relates to the field of antibody drugs. In particular, the present disclosure relates to claudin 18.2 antibodies and uses thereof. [Background technology]
[0003] The statements made in this specification are merely intended to provide background information related to the present disclosure and do not necessarily constitute prior art.
[0004] Claudin 18 (CLDN18) is a protein encoded by the human claudin 18 gene and belongs to the tight junction protein family found in cells. Claudin 18 can regulate the flow of molecules between cell layers.
[0005] Claudin 18 protein contains four transmembrane domains and two extracellular loops in its structure, with the N-terminus and C-terminus located inside the cytoplasm. Claudin 18 has two splicing variants, claudin 18.1 and claudin 18.2. The two sequences differ only by eight amino acids in the first extracellular loop. Claudin 18.1 is expressed and distributed differently from claudin 18.2. Claudin 18.1 is selectively expressed in normal lung cells, whereas claudin 18.2 expression is very limited in normal cells, but is very often ectopically activated and overexpressed in various tumors (gastric, lung, pancreatic, etc.). Claudin 18.2 has been postulated as a potential therapeutic target for gastric and other types of cancer. Discovery of this target also provides new options for treating gastric cancer. Summary of the Invention
[0006] The present disclosure provides anti-claudin 18.2 antibodies.
[0007] In some embodiments, the anti-claudin 18.2 antibody comprises a heavy chain variable region and a light chain variable region, i) the heavy chain variable region comprises the same HCDR1, HCDR2 and HCDR3 sequences as in the heavy chain variable region set forth in SEQ ID NO:3, and the light chain variable region comprises the same LCDR1, LCDR2 and LCDR3 sequences as in the light chain variable region set forth in SEQ ID NO:4; or ii) the heavy chain variable region comprises the same HCDR1, HCDR2 and HCDR3 sequences as in the heavy chain variable region set forth in SEQ ID NO: 5, and the light chain variable region comprises the same LCDR1, LCDR2 and LCDR3 sequences as in the light chain variable region set forth in SEQ ID NO: 6. In some embodiments, the anti-claudin 18.2 antibody comprises a heavy chain variable region and a light chain variable region, iii) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as set forth in SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14, respectively; or iv) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO:15, SEQ ID NO:16 and SEQ ID NO:17, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO:18, SEQ ID NO:19 and SEQ ID NO:20, respectively.
[0008] It should be understood by those skilled in the art that item numbers such as i), ii), a), b) are only for making the listed technical solutions or elements clearer and easier to identify, and do not limit the following technical solutions or elements in any way. When the same item numbers are used, this does not mean that the following technical solutions or elements are the same.
[0009] In some embodiments of the above anti-claudin 18.2 antibodies, the anti-claudin 18.2 antibody is a murine antibody, a chimeric antibody or a humanized antibody.
[0010] In some embodiments, the anti-claudin 18.2 antibody comprises a heavy chain variable region and a light chain variable region, (v) a heavy chain variable region having at least 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identity to the heavy chain variable region set forth in SEQ ID NO: 3 or 24 and a light chain variable region having at least 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identity to the light chain variable region set forth in SEQ ID NO: 4 or 21; or (vi) the heavy chain variable region has at least 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the heavy chain variable region set forth in SEQ ID NO: 5 or 31, and the light chain variable region has at least 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the light chain variable region set forth in SEQ ID NO: 6 or 28.
[0011] In some embodiments, the anti-claudin 18.2 antibody comprises a heavy chain variable region and a light chain variable region, (1) the amino acid sequence of the heavy chain variable region is as set forth in SEQ ID NO:3 or has at least 90% identity to SEQ ID NO:3, and the amino acid sequence of the light chain variable region is as set forth in SEQ ID NO:4 or has at least 90% identity to SEQ ID NO:4; (2) the amino acid sequence of the heavy chain variable region is as set forth in SEQ ID NO:24 or has at least 90% identity to SEQ ID NO:24, and the amino acid sequence of the light chain variable region is as set forth in SEQ ID NO:21 or has at least 90% identity to SEQ ID NO:21; (3) the amino acid sequence of the heavy chain variable region is as set forth in SEQ ID NO:5 or has at least 90% identity to SEQ ID NO:5, and the amino acid sequence of the light chain variable region is as set forth in SEQ ID NO:6 or has at least 90% identity to SEQ ID NO:6; or (4) The amino acid sequence of the heavy chain variable region is as set forth in SEQ ID NO:31 or has at least 90% identity to SEQ ID NO:31, and the amino acid sequence of the light chain variable region is as set forth in SEQ ID NO:28 or has at least 90% identity to SEQ ID NO:28.
[0012] In some embodiments of the above anti-claudin 18.2 antibody, the anti-claudin 18.2 antibody is a humanized antibody, the humanized antibody comprises framework regions derived from a human antibody framework region or a framework region variant thereof, the framework region variant having up to 10 back mutations in each of the human antibody light chain framework region and / or heavy chain framework region.
[0013] In some embodiments, the human antibody heavy chain framework region is identical to the framework region of the heavy chain variable region set forth in amino acid SEQ ID NO:24, or the human antibody light chain variable region is identical to the framework region of the light chain variable region set forth in amino acid SEQ ID NO:21; or the human antibody heavy chain framework region is identical to the framework region of the heavy chain variable region set forth in amino acid SEQ ID NO:31, or the human antibody light chain variable region is identical to the framework region of the light chain variable region set forth in amino acid SEQ ID NO:28.
[0014] In some embodiments, preferably the framework region variant comprises a mutation selected from (a) or (b) below: (a) one or more amino acid back-mutations of 22S, 85I, or 87H in the light chain variable region, and / or one or more back-mutations selected from the group consisting of 48I, 82T, and 69M in the heavy chain variable region; or (b) one or more amino acid back mutations selected from the group consisting of 4L and 22S in the light chain variable region, and / or one or more back mutations selected from the group consisting of 38K, 40R, 48I, 66K, 67A, 69, 71L and 73K in the heavy chain variable region.
[0015] In some embodiments of the above-described anti-claudin 18.2 antibodies, the framework region variant comprises a mutation selected from (a-1) or (b-1) below: (a-1) amino acid back mutations 22S, 85I, and 87H in the light chain variable region, and amino acid back mutations 48I and 82T in the heavy chain variable region; or (b-1) Amino acid back mutation 4L contained in the light chain variable region.
[0016] In some embodiments of the anti-claudin 18.2 antibody, (vii) the heavy chain variable region sequence is as set forth in SEQ ID NO:3 and the light chain variable region sequence is as set forth in SEQ ID NO:4; or (viii) the heavy chain variable region sequence is as set forth in SEQ ID NO:24, 25, 26, or 27 and the light chain variable region sequence is as set forth in SEQ ID NO:21, 22, or 23; or (ix) the heavy chain variable region sequence is as set forth in SEQ ID NO:5 and the light chain variable region sequence is as set forth in SEQ ID NO:6; or (x) the heavy chain variable region sequence is as set forth in SEQ ID NO:31, 32, 33, or 34, and the light chain variable region sequence is as set forth in SEQ ID NO:28, 29, or 30.
[0017] In some embodiments of the above-described anti-claudin 18.2 antibodies, or antigen-binding fragments thereof, the anti-claudin 18.2 antibodies comprise the heavy chain variable region and the light chain variable region shown below: (xi) a heavy chain variable region sequence set forth in SEQ ID NO: 31 and a light chain variable region sequence set forth in SEQ ID NO: 29; or (xii) a heavy chain variable region sequence as shown in SEQ ID NO: 26 and a light chain variable region sequence as shown in SEQ ID NO: 23.
[0018] In some embodiments of the above anti-claudin 18.2 antibodies, the light chain variable region and the heavy chain variable region may be a combination of the light chain variable region and the heavy chain variable region shown in the table below.
[0019] [Table 1]
[0020] [Table 2]
[0021] In some embodiments of the above anti-claudin 18.2 antibodies, the antibody further comprises an antibody constant region. In some specific embodiments, the heavy chain constant region of the antibody is selected from the group consisting of human IgG1, IgG2, IgG3 and IgG4 constant regions and variants thereof, and the light chain constant region of the antibody is selected from the group consisting of human antibody kappa, lambda chain constant regions and variants thereof. In some specific embodiments, the antibody has a heavy chain constant region sequence shown in SEQ ID NO: 7 and a light chain constant region sequence shown in SEQ ID NO: 8. In some specific embodiments, the antibody has a heavy chain having at least 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identity to the amino acid sequence shown in SEQ ID NO: 35 or 42, and a light chain having at least 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identity to the amino acid sequence shown in SEQ ID NO: 36 or 39; or a heavy chain having at least 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identity to the amino acid sequence set forth in SEQ ID NO: 37 or 49, and / or a light chain having at least 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identity to the amino acid sequence set forth in SEQ ID NO: 38 or 46. Includes.
[0022] In some embodiments, the anti-claudin 18.2 antibody is (c) a heavy chain depicted in SEQ ID NO:35 and / or a light chain depicted in SEQ ID NO:36; (d) a heavy chain depicted in SEQ ID NO: 42, 43, 44, or 45, and / or a light chain depicted in SEQ ID NO: 39, 40, or 41; (e) a heavy chain set forth in SEQ ID NO:37 and / or a light chain set forth in SEQ ID NO:38; or (f) a heavy chain depicted in SEQ ID NO: 49, 50, 51, or 52, and / or a light chain depicted in SEQ ID NO: 46, 47, or 48. Includes.
[0023] In some embodiments of the anti-claudin 18.2 antibody, the antibody competes with the anti-claudin 18.2 antibody, or an antigen-binding fragment thereof, for binding to human claudin 18.2.
[0024] In some embodiments, the anti-claudin 18.2 antibody is A heavy chain as set forth in amino acid sequence SEQ ID NO:44 and a light chain as set forth in SEQ ID NO:41; or Heavy chain shown in amino acid sequence SEQ ID NO:49 and light chain shown in SEQ ID NO:47 Includes.
[0025] Another aspect of the present disclosure also provides a nucleic acid molecule encoding the above-mentioned anti-claudin 18.2 antibody.
[0026] Another aspect of the disclosure also provides an expression vector comprising the above-described nucleic acid molecule.
[0027] Another aspect of the present disclosure also provides a host cell, preferably a bacterial cell, a fungal cell, an insect cell or a mammalian cell, comprising the above-mentioned nucleic acid molecule or the above-mentioned expression vector.
[0028] Another aspect of the present disclosure also provides an antibody-drug conjugate formed by conjugating the above-described anti-claudin 18.2 antibody to a cytotoxic drug.
[0029] Another aspect of the present disclosure also provides an antibody-drug conjugate comprising or consisting of the above-described anti-claudin 18.2 antibody covalently linked to a cytotoxic drug.
[0030] In some embodiments, the present disclosure provides a method for preparing the anti-claudin 18.2 antibody.
[0031] In some embodiments, the present disclosure provides a method for preparing the anti-claudin 18.2 antibody-drug conjugate.
[0032] In some embodiments, the present disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of the anti-claudin 18.2 antibody, or the nucleic acid molecule, or the antibody-drug conjugate, and one or more pharma- ceutically acceptable carriers, diluents, buffers, or excipients.
[0033] In some embodiments, the present disclosure provides a method for immunoassay or detection of claudin 18.2, comprising contacting the above-described anti-claudin 18.2 antibody with a sample to be tested.
[0034] In some embodiments, the present disclosure provides use of the above-mentioned anti-claudin 18.2 antibody for the preparation of a reagent for an immunoassay of human claudin 18.2.
[0035] In some embodiments, the present disclosure provides an anti-claudin 18.2 antibody as described above for use in an immunoassay or detection of claudin 18.2.
[0036] In some embodiments, the present disclosure provides a kit comprising the anti-claudin 18.2 antibody.
[0037] In some embodiments, the present disclosure relates to use of the anti-claudin 18.2 antibody or the nucleic acid molecule or the antibody-drug conjugate or the pharmaceutical composition for the preparation of a medicament for treating a cancer or tumor, wherein the cancer or tumor is preferably a claudin 18.2-positive cancer or malignant tumor, more preferably a head and neck squamous cell carcinoma, head and neck cancer, brain cancer, glioma, glioblastoma multiforme, neuroblastoma, central nervous system cancer, neuroendocrine tumor, pharyngeal cancer, nasopharyngeal cancer, esophageal cancer, thyroid cancer, malignant pleural mesothelioma, lung cancer, breast cancer, liver cancer, hepatocellular tumor, hepatocellular carcinoma, hepatobiliary cancer, liver and gallbladder cancer, cancer), pancreatic cancer, gastric cancer, gastrointestinal cancer, intestinal cancer, colon cancer, colorectal cancer, renal cancer, clear cell renal cell carcinoma, ovarian cancer, endometrial cancer, cervical cancer, bladder cancer, prostate cancer, testicular cancer, skin cancer, melanoma, leukemia, lymphoma, bone cancer, chondrosarcoma, myeloma, multiple myeloma, myelodysplastic syndrome, myeloproliferative neoplasms, squamous cell carcinoma, Ewing's sarcoma, systemic light-chain amyloidosis, and Merkel cell carcinoma; lymphoma is Hodgkin's lymphoma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, the lung cancer is selected from the group consisting of non-small cell lung cancer and small cell lung cancer; the leukemia is selected from the group consisting of chronic myeloid leukemia, acute myeloid leukemia, lymphocytic leukemia, lymphoblastic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia and myeloid leukemia.
[0038] In some embodiments, the present disclosure relates to a method for treating a disease associated with claudin 18.2, comprising administering a therapeutically effective amount of the anti-claudin 18.2 antibody or the nucleic acid molecule or the antibody-drug conjugate or the pharmaceutical composition to a subject, wherein the disease is preferably a cancer or tumor, more preferably a claudin 18.2-positive cancer or malignant tumor, more preferably a head and neck squamous cell carcinoma, head and neck cancer, brain cancer, glioma, glioblastoma multiforme, neuroblastoma, central nervous system cancer, neuroendocrine tumor, pharyngeal cancer, nasopharyngeal carcinoma, The present invention provides a method for treating cancer selected from the group consisting of esophageal cancer, thyroid cancer, malignant pleural mesothelioma, lung cancer, breast cancer, liver cancer, hepatocellular tumor, hepatocellular carcinoma, hepatobiliary cancer, pancreatic cancer, gastric cancer, gastrointestinal cancer, intestinal cancer, colon cancer, colorectal cancer, kidney cancer, clear cell renal cell carcinoma, ovarian cancer, endometrial cancer, cervical cancer, bladder cancer, prostate cancer, testicular cancer, skin cancer, melanoma, leukemia, lymphoma, bone cancer, chondrosarcoma, myeloma, multiple myeloma, myelodysplastic syndrome, myeloproliferative neoplasm, squamous cell carcinoma, Ewing's sarcoma, systemic light chain amyloidosis, and Merkel cell carcinoma. More preferably, the lymphoma is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, primary mediastinal large B-cell lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, T-cell / histiocyte-rich large B-cell lymphoma and lymphoplasmacytic lymphoma; the lung cancer is selected from the group consisting of non-small cell lung cancer and small cell lung cancer; and the leukemia is selected from the group consisting of chronic myeloid leukemia, acute myeloid leukemia, lymphocytic leukemia, lymphoblastic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia and myeloid leukemia.
[0039] In some embodiments, a therapeutically effective amount refers to 0.1 mg to 3000 mg or 1 mg to 1000 mg of the anti-claudin 18.2 antibody or the antibody-drug conjugate contained in a unit dose of the composition.
[0040] In some embodiments, the present disclosure relates to the anti-claudin 18.2 antibody, the nucleic acid molecule, the antibody-drug conjugate, or the pharmaceutical composition for use in treating a disease associated with claudin 18.2, wherein the disease is preferably a cancer or tumor, more preferably a claudin 18.2-positive cancer or malignant tumor, more preferably a head and neck squamous cell carcinoma, head and neck cancer, brain cancer, glioma, glioblastoma multiforme, neuroblastoma, central nervous system cancer, neuroendocrine tumor, pharyngeal cancer, nasopharyngeal cancer, esophageal cancer, thyroid cancer, malignant pleural mesothelioma, lung cancer, breast cancer, or liver cancer. the anti-claudin 18.2 antibody, the nucleic acid molecule, the antibody-drug conjugate, or the pharmaceutical composition is selected from the group consisting of hepatocellular tumor, hepatocellular carcinoma, hepatobiliary cancer, pancreatic cancer, gastric cancer, gastrointestinal cancer, intestinal cancer, colon cancer, colorectal cancer, renal cancer, clear cell renal cell carcinoma, ovarian cancer, endometrial cancer, cervical cancer, bladder cancer, prostate cancer, testicular cancer, skin cancer, melanoma, leukemia, lymphoma, bone cancer, chondrosarcoma, myeloma, multiple myeloma, myelodysplastic syndrome, myeloproliferative neoplasm, squamous cell carcinoma, Ewing's sarcoma, systemic light-chain amyloidosis, and Merkel cell carcinoma. More preferably, the lymphoma is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, primary mediastinal large B-cell lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, T-cell / histiocyte-rich large B-cell lymphoma and lymphoplasmacytic lymphoma; the lung cancer is selected from the group consisting of non-small cell lung cancer and small cell lung cancer; and the leukemia is selected from the group consisting of chronic myeloid leukemia, acute myeloid leukemia, lymphocytic leukemia, lymphoblastic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia and myeloid leukemia.
[0041] In some embodiments, the cancer is gastric cancer, esophageal cancer, lung cancer, or pancreatic cancer.
[0042] In some embodiments, the antibody or antibody-drug conjugate can have a therapeutic effect on cancers with high, moderate and low expression of claudin 18.2, as described above.
[0043] The claudin 18.2 antibodies and antibody-drug conjugates provided in the present disclosure have excellent affinity for cell surface antigens, favorable endocytosis efficiency, potent tumor-inhibiting efficiency, and broader pharmaceutical application range, making them suitable for clinical use as medicines. [Brief description of the drawings]
[0044] [Figure 1] FACS study results of humanized antibody binding to human claudin 18.2 at the cellular level. [Diagram 2] Endocytosis assay of humanized antibodies in NUGC4 cells. [Diagram 3] 3 shows the detection of the ADCC effect of an antibody on NUGC4 cells with different levels of claudin 18.2 expression. FIG. 3A shows the detection of the ADCC effect of an antibody on wild-type NUGC4 cells (low expression of claudin 18.2). FIG. 3B shows the detection of the ADCC effect of an antibody on NUGC4 cells with moderate expression of claudin 18.2. FIG. 3C shows the detection of the ADCC effect of an antibody on NUGC4 cells with high expression of claudin 18.2. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0045] term In order to make this disclosure more readily understandable, certain technical and scientific terms are precisely defined below. Unless expressly defined otherwise herein, all other technical and scientific terms used herein have the meaning commonly understood by those of ordinary skill in the art to which this disclosure belongs.
[0046] The three letter and one letter codes for amino acids used in this disclosure are as set forth in J. Biol. Chem, 243, p3558 (1968).
[0047] The term "cytotoxic agent" refers to a substance that inhibits or prevents the function of cells and / or causes cell death or destruction. Cytotoxic agents include compounds that can be used to kill cells, such as toxins and chemotherapeutic drugs.
[0048] The term "toxin" refers to any substance that allows for cell growth or proliferation, and such substances may be small molecule toxins and their derivatives of bacterial, fungal, plant or animal origin, including camptothecin derivatives such as exatecan, maytansinoids and maytansinoid derivatives such as DM1, DM3, DM4 (CN101573384), auristatin F (AF) and auristatin F derivatives such as MMAF, MMAE, 3024 (WO2016 / 127790A1, compound 7), diphtheria toxin, exotoxin, ricin A chain, abrin A chain, modeccin, α-sarcin, Aleutites fordii toxic protein, dianthin toxic protein, Phytolacca americana toxic proteins (PAPI, PAPII and PAP-S), Momordica charantia, and the like. charantia inhibitors, curcin, crotin, Sapaonaria officinalis inhibitors, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the trichothecenes.
[0049] The term "chemotherapeutic agent" refers to a chemical compound that can be used for the treatment of tumors. This definition also includes anti-hormonal agents that can regulate, reduce, block or inhibit hormone action that can promote cancer growth, generally in a systemic manner or in a systemic therapeutic manner. The chemotherapeutic agent itself may be a hormone. Examples of chemotherapy drugs include alkylating agents such as thiotepa; cyclosulfamide (Cytoxan™); alkylsulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benaodopa, carboquone, meturedopa, and uredopa; aziridines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylolmelamine; nitrogen mustards such as chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethaminoxide; melphalan, novembichin, phenesterine, prednimustine, trofosfamide, Uramustine; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; clarithromycin, actinomycin, autramycin, azaserine, bleomycin, cactinomycin, calicheamicin, carabicin, chromomycin, carzinophilin, chromomycin, actinomycin D, daunorubicin, detorubicin in), 6-diazo-5-oxy-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcelomycin, mitomycin, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, and other antibiotics;Streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; metabolic antagonists such as methotrexate and 5-FU; folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; methotrexate analogues such as fludarabine, 6-mercaptopterin, thiomethopterin, thioguanopterin; pyrimidine analogues such as ancitabine, azacytidine, 6-azuridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, fluorouridine, 5-FU; androgens such as calsterone, dromostanolong propionate, epithiostanol, mepitiostane, testolactone; antiadrenergic agents such as aminoglutethimide, mitotane, trilostane; folinic acid, etc. Folic acid supplements;Glucuronide;Aldophosphamide glycosides;Aminolevulinic acid;Amsacrine;Bestravcil;Bisantrene;Edatraxate;Defofamine;Colchicine;Diaziquone;Elfomithine;Elliptinium acetate;Ethoglucide;Gallium nitrate;Hydroxyurea;Lentinan;Lonidamine;Mitoguazone;Mitoxantrone;Mopidamol;Nitracrine;Pintostatin;Phenamet;Pirarubicin;Podophyllic acid;2-Ethylhydrazide;Procarbazine;PSK;Razoxane;Schizophyllan;Spirogermanium;Alternaria tenas tenuis) keto acids; triimine quinones; 2,2',2''-trichlorotriethylamine; urethanes; vinblastinamide; dacarbazine; mannitol mustard; mitobronitol; dibromo euonymus alcohol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxanes such as paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology, Princeton, NJ) and docetaxel (TAXOTERE®, Rhone-Poulenc Rorer, Antony, France);Chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosphate; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunorubicin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS2000; difluoromethylornithine (DMFO); esperamicin retinoic acid; capecitabine; and pharmacologic acceptable salts, acids, or derivatives of any of the above substances. The above definition also includes antihormonal agents that can modulate or inhibit the effect of hormones on tumors. For example, antiestrogens include tamoxifen, raloxifene, aromatase inhibitor 4(5)-imidazole, 4-hydroxyl tamoxifen, trioxyfene, ketoxifene, LY117018, onapristone, and toremifene (Fareston); and antiandrogens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and pharma- ceutically acceptable salts, acids, or derivatives of any of the above substances;
[0050] As used herein, "antibody" refers to an immunoglobulin, and a complete antibody is a structure consisting of four peptide chains formed by two identical heavy chains linked to two identical light chains by interchain disulfide bonds. The immunoglobulin heavy chain constant regions exhibit different amino acid compositions and arrangements, and therefore different antigenicity. Thus, immunoglobulins can be classified into five types, or sometimes called immunoglobulin isotypes, namely IgM, IgD, IgG, IgA, and IgE, with the corresponding heavy chains being μ, δ, γ, α, and ε, respectively. Depending on the amino acid composition of the hinge region and the composition and location of the heavy chain disulfide bonds, the same type of Ig can be further classified into different subtypes, for example, IgG can be classified into IgG1, IgG2, IgG3, and IgG4. The light chain can be classified into κ or λ chains based on the different constant regions. Each of the five types of Ig can have a κ or λ chain.
[0051] Approximately 110 amino acid sequences adjacent to the N-terminus of antibody heavy and light chains are highly variable and are known as the variable region (Fv region); the remainder of the amino acid sequence near the C-terminus is relatively stable and is known as the constant region. The variable region contains three hypervariable regions (HVR) and four framework regions (FR) with relatively conserved sequences. The three hypervariable regions that determine the specificity of the antibody are also known as complementarity determining regions (CDR). Each light chain variable region (VL) and each heavy chain variable region (VH) consists of three CDR regions and four FR regions, in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The three CDR regions of the light chain are referred to as LCDR1, LCDR2 and LCDR3, and the three CDR regions of the heavy chain are referred to as HCDR1, HCDR2 and HCDR3.
[0052] The antibodies of the present disclosure include murine antibodies, chimeric antibodies and humanized antibodies.
[0053] As used herein, the term "mouse antibody" refers to an anti-human claudin 18.2 monoclonal antibody prepared according to the knowledge and skill in the art. In the preparation, claudin 18.2 or an epitope thereof is injected as an antigen into a test subject, and then a hybridoma expressing an antibody having a desired sequence or functional characteristics is isolated. In a preferred embodiment of the present disclosure, the mouse claudin 18.2 antibody or antigen-binding fragment thereof further comprises a light chain constant region of a mouse kappa chain, lambda chain or variants thereof, or further comprises a heavy chain constant region of a mouse IgG1, IgG2, IgG3 or variants thereof.
[0054] The term "chimeric antibody" refers to an antibody obtained by fusing the variable region of a mouse antibody with the constant region of a human antibody, and such an antibody can alleviate the immune response induced by mouse antibodies. To establish a chimeric antibody, first, a hybridoma secreting a specific mouse monoclonal antibody is established, and the variable region gene is cloned from the mouse hybridoma. Then, if necessary, the constant region gene is cloned from a human antibody. The mouse variable region gene is linked to a human constant region gene to form a chimeric gene, which can then be inserted into an expression vector. Finally, the chimeric antibody molecule is expressed in a eukaryotic or prokaryotic system. In a preferred embodiment of the present disclosure, the antibody light chain of the chimeric antibody further comprises a light chain constant region of a human kappa chain, a lambda chain, or a variant thereof. The antibody heavy chain of the claudin 18.2 chimeric antibody further comprises a heavy chain constant region of human IgG1, IgG2, IgG3, IgG4 or a variant thereof, and preferably comprises a heavy chain constant region of human IgG1, IgG2 or IgG4, or comprises a heavy chain constant region of IgG1, IgG2 or IgG4 with amino acid mutations (such as an L234A mutation and / or an L235A mutation and / or an S228P mutation).
[0055] The term "humanized antibody", also known as CDR-grafted antibody, refers to an antibody generated by grafting non-human CDR sequences onto a human antibody variable region framework, i.e., an antibody generated in a different type of human germline antibody framework sequence. Humanized antibodies can avoid xenogeneic reactions induced by chimeric antibodies with multiple heterogeneous protein components. Such framework sequences can be obtained from public DNA databases or published references that list germline antibody gene sequences. For example, germline DNA sequences of human heavy and light chain variable region genes can be found in the "VBase" human germline sequence database (available at www.mrccpe.com.ac.uk / vbase) or in Kabat, EA et al. 1991 Sequences of Proteins of Immunological Interest, 5th Edition. To avoid reduced activity caused by reduced immunogenicity, the framework sequences in the human antibody variable regions may undergo minimal reverse-mutations or back mutations to maintain activity. The humanized antibodies of the present disclosure also refer to humanized antibodies in which CDR affinity maturation has been performed by yeast display.
[0056] In one embodiment of the disclosure, the antibody or antigen-binding fragment thereof further comprises a light chain constant region derived from a human or mouse κ chain, λ chain, or a variant thereof, or further comprises a heavy chain constant region derived from a human or mouse IgG1, IgG2, IgG3, IgG4, or a variant thereof; preferably, a heavy chain constant region derived from human IgG1, IgG2, or IgG4, or an IgG1, IgG2, or IgG4 variant with amino acid mutations (such as the L234A mutation and / or the L235A mutation and / or the S228P mutation).
[0057] As described herein, "variants" of the heavy and light chain constant regions of human antibodies refer to heavy or light chain constant region variants disclosed in the prior art without alteration of the structure and function of the antibody variable region. Exemplary variants include IgG1, IgG2, IgG3 or IgG4 heavy chain constant region variants obtained by site-specific modifications and amino acid substitutions to the heavy chain constant region. Specific substitutions are, for example, YTE mutations, L234A and / or L235A mutations, S228P mutations, and / or mutations resulting in a knob-into-hole structure (whereby the antibody heavy chain has a combination of knob-type Fc and hole-type Fc). These mutations have been demonstrated to confer new properties to antibodies without altering the function of the antibody variable region.
[0058] "Human antibody (HuMAb)", "antibody derived from a human", "fully human antibody" and "fully human type antibody" are used interchangeably and may be an antibody derived from a human or from a genetically modified organism that has been "modified" by any method known in the art to generate specific human antibodies in response to antigenic stimulation. In some techniques, elements of human heavy and light chain loci are introduced into cell lines derived from embryonic stem cell lines, with the goal of disrupting the endogenous heavy and light chain loci. The transgenic organism is capable of synthesizing human antibodies specific to human antigens and can be used to produce hybridomas that secrete human antibodies. Human antibodies may be such that the heavy and light chains are encoded by nucleotide sequences derived from one or more human DNA sources. Fully human antibodies can be constructed by genetic or chromosomal transfection methods and phage display techniques, or from in vitro activated B cells, all of which are known in the art.
[0059] The terms "full-length antibody", "complete antibody", "whole antibody" and "complete antibody" are used interchangeably herein and refer to an antibody in substantially its entire form, as distinguished from an antigen-binding fragment, as defined below. The foregoing terms strictly refer to an antibody comprising the constant regions in the light and heavy chains. "Antibody" in the present disclosure includes "full-length antibodies" and antigen-binding fragments thereof.
[0060] In some embodiments, the full-length antibody of the present disclosure includes a full-length antibody formed by linking a light chain variable region with a light chain constant region and linking a heavy chain variable region with a heavy chain constant region as shown in the light chain and heavy chain combination in the table below. Those skilled in the art can select light chain constant regions and heavy chain constant regions, such as light chain constant regions and heavy chain constant regions derived from human antibodies, from various antibody sources according to actual needs.
[0061] The term "antigen-binding fragment" or "functional fragment" refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., claudin 18.2). It has been shown that fragments of full-length antibodies can be used to acquire antigen-binding function. Examples of binding fragments encompassed by the term "antigen-binding fragment" of an antibody include (i) a Fab fragment, which is a monovalent fragment composed of the VL, VH, CL and CH1 domains; (ii) a F(ab')2 fragment, which is a bivalent fragment formed by two Fab fragments linked by a disulfide bridge in the hinge region; (iii) an Fd fragment composed of the VH and CH1 domains; (iv) an Fv fragment composed of the VH and VL domains belonging to one of the arms of the antibody; (v) a dsFv, which is an antigen-binding fragment formed by VH and VL via an interchain disulfide bond; and (vi) bispecific, diabody and multispecific antibody containing fragments such as scFv, dsFv and Fab. Furthermore, the VL and VH domains of the Fv fragment are linked by a synthetic linker to generate a single protein chain (called single-chain Fv (scFv) (see, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci USA 85:5879-5883) which is a monovalent molecule formed by pairing of the VL and VH domains. Such single-chain antibodies are also included in the term "antigen-binding fragment" of an antibody. Such antibody fragments are obtained using conventional techniques known in the art and are screened for functional fragments using the same methods as for intact antibodies. Antigen-binding portions can be produced by recombinant DNA techniques or by enzymatic or chemical destruction of intact immunoglobulins. The antibodies can be in the form of different isotypes, for example IgG (for example IgG1, IgG2, IgG3 or IgG4 subtypes), IgA1, IgA2, IgD, IgE or IgM antibodies.
[0062] Fab is an antibody fragment having antigen-binding activity obtained by treating an IgG antibody molecule with an enzyme having the same activity as papain.
[0063] F(ab')2 is an antibody fragment having antigen-binding activity obtained by digesting IgG with an enzyme having the same activity as pepsin.
[0064] Fab' is an antibody fragment having antigen-binding activity obtained by cleaving the above-mentioned F(ab')2.
[0065] Furthermore, Fab' can be produced by inserting DNA encoding the Fab' fragment into an expression vector and introducing the vector into a host.
[0066] The term "single chain antibody", "single chain Fv" or "scFv" refers to a molecule comprising an antibody heavy chain variable domain (or region; VH) linked by a linker to an antibody light chain variable domain (or region; VL). Such scFv molecules have the general structure NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. Other linkers that can be used in the present disclosure are described in the literature, including but not limited to, Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Alfthan et al. (1995), Protein Eng. 8:725-731; Choi et al. (2001), Eur. J. Immunol. 31:94-106; Hu et al. (1996), Cancer Res. 56:3055-3061; Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001), Cancer Immunol.
[0067] A bispecific antibody is an antibody fragment in which scFv or Fab are dimerized and has bivalent antigen-binding activity. These bivalent antigen-binding activities for two antigens may be the same or different.
[0068] Bispecific and multispecific antibodies refer to antibodies capable of binding to more than one antigen or antigenic determinant.
[0069] dsFv can be obtained by substituting one amino acid residue in each of VH and VL with a cysteine residue, and then linking the substituted polypeptides by a disulfide bond between the two cysteine residues. The amino acid residue to be substituted with a cysteine residue can be selected based on the three-dimensional structure prediction of an antibody by a known method (e.g., Protein Engineering, 7, 697 (1994)).
[0070] The term "amino acid difference" or "amino acid mutation" refers to an amino acid change or mutation in a protein or polypeptide variant compared to an original protein or polypeptide, and includes an insertion, deletion or substitution of one, two or more amino acids relative to the original protein or polypeptide.
[0071] The term "antibody framework" or "FR region" refers to that part of a variable domain, either VL or VH, that serves as a scaffold for the antigen binding loops (CDRs) of this variable domain. Essentially, an "antibody framework" or "FR region" is a variable domain without the CDRs.
[0072] The term "complementarity determining region", "CDR" or "hypervariable region" refers to one of the six hypervariable regions present in an antibody variable domain that are primarily responsible for antigen binding. Generally, there are three CDRs (HCDR1, HCDR2, HCDR3) in each heavy chain variable region and three CDRs (LCDR1, LCDR2, LCDR3) in each light chain variable region. The amino acid sequence boundaries of the CDRs can be determined according to any of a variety of well-known schemes, including the "Kabat" numbering system (see Kabat et al. (1991), Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD), the "Chothia" numbering system (see Al-Lazikani et al. (1997) JMB 273:927-948), and the ImmunoGenTics (IMGT) numbering system (Lefranc MP, Immunologist, 7, 132-136 (1999); Lefranc, MP et al., Dev. Comp. Immunol., 27, 55-77 (2003)). For example, for classical formats, according to the Kabat system, the CDR amino acid residues in the heavy chain variable domain (VH) are numbered as 31-35 (HCDR1), 50-65 (HCDR2) and 95-102 (HCDR3); the CDR amino acid residues in the light chain variable domain (VL) are numbered as 24-34 (LCDR1), 50-56 (LCDR2) and 89-97 (LCDR3). According to the Chothia system, the CDR amino acid residues in the VH are numbered as 26-32 (HCDR1), 52-56 (HCDR2) and 95-102 (HCDR3); the amino acid residues in the VL are numbered as 26-32 (LCDR1), 50-52 (LCDR2) and 91-96 (LCDR3).By combining the Kabat and Chothia formulas to define CDRs, the CDRs are composed of amino acid residues 26-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3) in human VH, and amino acid residues 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3) in human VL. According to the IMGT standards, the CDR amino acid residues in VH are generally numbered as 26-35 (CDR1), 51-57 (CDR2), and 93-102 (CDR3), and the CDR amino acid residues in VL are generally numbered as 27-32 (CDR1), 50-52 (CDR2), and 89-97 (CDR3). According to the IMGT criteria, the CDR regions of an antibody can be determined by the IMGT / DomainGap Align Program.
[0073] The term "epitope" or "antigenic determinant" refers to a site on an antigen (e.g., a specific site on a claudin 18.2 molecule) to which an immunoglobulin or antibody binds. An epitope generally includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 contiguous or non-contiguous amino acids of a unique tertiary structure. See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, edited by GE Morris (1996).
[0074] The terms "specifically bind," "selectively bind," "selective binding," or "specific binding" refer to the binding of an antibody to a predetermined epitope on an antigen. Generally, an antibody binds to a given epitope on an antigen at a concentration of about 10 -8 Less than m, e.g., about 10 -9 Less than M, 10 -10 Less than M, 10 -11 Less than M, 10 -12 It binds with an affinity (KD) less than M or lower.
[0075] The term "KD" refers to the dissociation equilibrium constant for a particular antibody-antigen interaction. Generally, the antibodies of the present disclosure have a dissociation equilibrium constant of about 10 -7 Less than m, e.g., about 10 -8 Less than M or 10 -9 The antibodies of the present disclosure bind to claudin 18.2 or an epitope thereof with a dissociation equilibrium constant (KD) of less than M, and the affinity of the antibodies of the present disclosure for, for example, cell surface antigens, was determined by measuring the KD value by FACS.
[0076] When the term "competition" is used in the context of antigen-binding proteins that compete for the same epitope, it means that competition occurs between the antigen-binding proteins, as determined by an assay in which a test antigen-binding protein (e.g., an antibody or functional fragment thereof) blocks or inhibits (e.g., reduces) the specific binding of a reference antigen-binding protein (e.g., a ligand or reference antibody) to a common antigen (e.g., claudin 18.2 antigen or a fragment thereof). Numerous types of competitive binding assays are available for determining whether one antigen-binding protein competes with another antigen-binding protein. These assays include, for example, solid-phase direct or indirect radioimmunoassays (RIA), solid-phase direct or indirect enzyme immunoassays (EIA), competitive sandwich assays (see, e.g., Stahli et al., 1983, Methods in Enzymology 9:242-253); solid-phase direct biotin-avidin EIA (see, e.g., Kirkland et al., 1986, J. Immunol. 137:3614-3619); solid-phase controlled label assays; solid-phase controlled label sandwich assays (see, e.g., Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press); solid-phase controlled label RIA using I-125 label (see, e.g., Morel et al., 1988, Molec. Immunol. 25:7-15); solid-phase direct biotin-avidin EIA (see, e.g., Cheung et al., 1990, Virology 176:546-552; and controlled label RIA (Moldenhauer et al., 1990, Scand. J. Immunol. 32:77-82). Generally, the assay involves the use of purified antigen that can bind to a solid surface or cells bearing both an unlabeled test antigen-binding protein and a labeled reference antigen-binding protein. Competitive inhibition is determined by measuring the amount of label bound to the solid surface or cells in the presence of the test antigen-binding protein. Typically, the test antigen-binding protein is present in excess.Antigen-binding proteins identified by competitive assays (competing with antigen-binding proteins) include antigen-binding proteins that bind to the same epitope as the reference antigen-binding protein; and antigen-binding proteins that bind to an epitope that is sufficiently close to the epitope bound by the reference antigen-binding protein, such that these two epitopes spatially interfere with each other to prevent binding. Further details regarding methods for determining competitive binding are provided in the Examples herein. Generally, when a competing antigen-binding protein is present in excess, it inhibits (e.g., reduces) at least 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, or 75% or more of the specific binding of the reference antigen-binding protein to the common antigen. In some cases, said binding is inhibited by at least 80-85%, 85-90%, 90-95%, 95-97%, or 97% or more.
[0077] As used herein, the term "nucleic acid molecule" refers to DNA molecules and RNA molecules. A nucleic acid molecule may be single-stranded or double-stranded, preferably double-stranded DNA or single-stranded or modified mRNA. A nucleic acid is "operably linked" when it is placed in a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.
[0078] "Identity" of an amino acid sequence refers to the percentage of amino acid residues that are identical between a first sequence and a second sequence when the amino acid sequences are aligned (and gaps are introduced as necessary) to give the maximum percentage of sequence identity, and any conservative substitutions are not considered as part of the sequence identity. To determine the percentage of amino acid sequence identity, alignment can be achieved by various methods within the scope of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can determine suitable parameters for measuring alignment, including any algorithms required to obtain maximum alignment over the entire length of the sequences being compared.
[0079] The term "expression vector" refers to a nucleic acid molecule that allows the transport of another nucleic acid to which it is linked. In one embodiment, the vector is a "plasmid", which refers to a circular double-stranded DNA loop into which additional DNA segments can be ligated. In another embodiment, the vector is a viral vector into which additional DNA segments can be ligated into the viral genome. The vectors disclosed herein can be autonomously replicated in a host cell into which they are introduced (e.g., bacterial vectors with a bacterial origin of replication and episomal mammalian vectors), or can be integrated into the genome of the host cell upon introduction into the host cell, thereby replicating together with the host genome (e.g., non-episomal mammalian vectors).
[0080] Methods for producing and purifying antibodies and antigen-binding fragments are well known in the art, e.g., Antibodies: a Laboratory Manual, Cold Spring Harbor, New York, Chapters 5-8 and 15. For example, mice can be immunized with human claudin 18.2 or a fragment thereof, and the resulting antibodies can then be renatured, purified, and sequenced by conventional methods well known in the art. Antigen-binding fragments can also be prepared by conventional methods. The antibodies or antigen-binding fragments of the present disclosure are modified to incorporate one or more human framework regions into the CDR regions derived from a non-human antibody. Human FR germline sequences can be obtained from ImMunoGeneTics (IMGT) via the website http: / / imgt.cines.fr, or from The Immunoglobulin Facts Book, 2001, ISBN 012441351, by alignment against the IMGT human antibody variable germline gene database using MOE software.
[0081] The term "host cell" refers to a cell into which an expression vector has been introduced. Host cells may include bacterial cells, microbial cells, plant cells, or animal cells. Bacteria susceptible to transformation include members of the Enterobacteriaceae, such as Escherichia coli or Salmonella strains; Bacillaceae, such as Bacillus subtilis; Pneumococcus; Streptococcus, and Haemophilus influenzae. Suitable microorganisms include Saccharomyces cerevisiae and Pichia pastoris. Suitable animal host cell lines include CHO (Chinese Hamster Ovary cell line), 293 cells, and NS0 cells.
[0082] The antibody or antigen-binding fragment of the present disclosure can be prepared and purified by conventional methods. For example, the cDNA sequences encoding the heavy and light chains can be cloned and recombined into an expression vector. The expression vector of the recombinant immunoglobulin can be stably transfected into a host cell. In one preferred prior art, the antibody can be glycosylated by a mammalian expression system, especially at the highly conserved N-terminal position belonging to the Fc region. Stable clones can be obtained by expressing an antibody that specifically binds to human claudin 18.2. Positive clones can also be expanded in a bioreactor to produce the antibody. The medium into which the antibody is secreted can be purified by conventional techniques. For example, purification can be performed by a Protein A or G Sepharose FF column adjusted with a buffer. Non-specific binding components are washed away. The bound antibody is eluted by a pH gradient, the antibody fragments are detected by SDS-PAGE, and then pooled. The antibody can be filtered and concentrated using common techniques. Soluble fragments and multimers can be effectively removed by common techniques such as size exclusion or ion exchange. The resulting product may then be immediately frozen, for example at -70°C, or lyophilized.
[0083] "Administration," "medication," or "treatment," when applied to an animal, human, experimental subject, cell, tissue, organ, or biological fluid, refers to contacting an exogenous pharmaceutical, therapeutic, diagnostic, or composition with an animal, human, subject, cell, tissue, organ, or biological fluid. "Administration," "medication," or "treatment" can refer to, for example, therapeutic, pharmacokinetic, diagnostic, research, and experimental methods. Treatment of a cell includes contacting a reagent with the cell and contacting a reagent with a fluid and then contacting the cell. "Administration," "medication," or "treatment" also refers to treating, for example, a cell with a reagent, diagnostic, binding compound, or another cell, in vitro or ex vivo. "Treatment," when applied to a human, veterinary, or research subject, refers to therapeutic treatments, prophylactic or preventative measures, research, and diagnostic applications.
[0084] "Treat" means administering a therapeutic agent, such as a composition comprising any of the antibodies or antigen-binding fragments of the present disclosure, either internally or externally, to a patient with one or more disease symptoms against which the therapeutic agent is known to have therapeutic activity. In general, the therapeutic agent is given in an amount effective to alleviate one or more disease symptoms in the patient or population to be treated, thereby inducing regression of such symptoms to any clinically measurable degree, or inhibiting the progression of such symptoms. The amount of therapeutic agent effective to alleviate any particular disease symptom (also called a "therapeutically effective amount") may vary depending on various factors, such as the disease state, age, and weight of the patient, and the ability of the drug to induce a desired response in the patient. Whether a disease symptom has been alleviated can be assessed by any clinical measurement commonly used by a physician or other skilled medical practitioner to assess the severity or progression of the condition. An embodiment of the present disclosure (e.g., a method of treatment or article of manufacture) may not be effective in alleviating a targeted disease symptom in every patient, but should alleviate a targeted disease symptom in a statistically significant number of patients as determined by any statistical test known in the art, such as Student's t-test, chi-square test, Mann-Whitney U test, Kruskal-Wallis test (H test), Jonkheel-Tapstra test, and Wilcoxon test.
[0085] "Conservative modification" or "conservative substitution or replacement" refers to the substitution of amino acids in a protein with other amino acids having similar properties (e.g., charge, size of side chain, hydrophobicity / hydrophilicity, backbone conformation and rigidity, etc.) so that changes can be made frequently without changing the biological activity of the protein. Those skilled in the art know that single amino acid substitutions in non-essential regions of a polypeptide generally do not substantially change the biological activity (see, for example, Watson et al. (1987) Molecular Biology of the Gene, The Benjamin / Cummings Pub. Co., p. 224, 4th ed.). Moreover, substitution with structurally or functionally similar amino acids is unlikely to disrupt biological activity. Exemplary conservative substitutions are listed in the table below under "Exemplary Amino Acid Conservative Substitutions."
[0086] [Table 3]
[0087] An "effective amount" or "effective dose" refers to the amount of a medicament, compound, or pharmaceutical composition required to obtain any one or more beneficial or desired results. For prophylactic applications, beneficial or desired results include eliminating or reducing the risk, reducing the severity, or delaying the onset of disease, including biochemical, histological, and behavioral signs of a condition, complications of a condition, and intermediate pathological phenotypes during the development of a condition. For therapeutic applications, beneficial or desired results include clinical results such as reducing the incidence of various conditions associated with the target antigen of the present disclosure or ameliorating one or more symptoms of such conditions, reducing the dosage of other agents required to treat the aforementioned conditions, improving the efficacy of another agent, and / or delaying the progression of a condition associated with the target antigen of the present disclosure in a patient.
[0088] "Exogenous" refers to a material produced outside an organism, cell, or human, as the case may be.
[0089] "Endogenous" refers to a substance produced within a cell, organism, or body, as the case may be.
[0090] "Identity" refers to the sequence similarity between two polynucleotide sequences or two polypeptide sequences. If a position in both of the two sequences to be compared is occupied by the same base or amino acid monomer subunit, for example, if a position in each of the two DNA molecules is occupied by adenine, then the molecules are homologous at said position. The percentage of identity between two sequences is a function of the number of matching or homologous positions shared by the two sequences, divided by the number of positions to be compared, and then multiplied by 100. For example, when two sequences are optimally aligned, if 6 out of 10 positions in the two sequences are matching or homologous, then the two sequences are 60% homologous; if 95 out of 100 positions in the two sequences are matching or homologous, then the two sequences are 95% homologous. Generally, when two sequences are aligned, the comparison is performed to give the maximum percentage of identity. For example, the comparison can be carried out by the BLAST algorithm, in which the parameters of the algorithm are selected to give the maximum match between each sequence over the entire length of each reference sequence.The following references refer to the BLAST algorithm that is frequently used for sequence analysis: BLAST algorithm (BLAST ALGORITHMS): Altschul, SF et al., (1990) J. Mol. Biol. 215: 403-410; Gish, W. et al., (1993) Nature Genet. 3: 266-272; Madden, TL et al., (1996) Meth. Enzymol. 266: 131-141; Altschul, SF et al., (1997) Nucleic Acids Res. 25: 3389-3402; Zhang, J. et al., (1997) Genome Res. 7: 649-656. Other conventional BLAST algorithms, such as that available from NCBI BLAST, are also well known to those of skill in the art.
[0091] As used herein, the terms "cell," "cell line," and "cell culture" are used interchangeably, and all such designations include progeny. Thus, "transformants" and "transformed cells" include the primary subject cell and cultures derived from that cell, regardless of the number of passages. It should also be understood that all progeny may not be precisely identical in DNA content due to intentional or unintentional mutations. Mutant progeny that have the same function or biological activity as screened for in the originally transformed cell are also included. Where distinct designations are intended, this will be clearly understood from the context.
[0092] "Isolated" refers to a molecule that is substantially free of other biological molecules, such as nucleic acids, proteins, lipids, carbohydrates, or other substances such as cell debris and growth medium. In general, the term "isolated" is not intended to mean the complete absence of such substances, or the absence of water, buffers, or salts, unless such substances are present in amounts that would significantly interfere with the experimental or therapeutic use of the compounds described herein.
[0093] "Optionally" or "optionally" means that the subsequent event or circumstance may occur, but does not necessarily occur, but the description includes cases where the event or circumstance occurs or does not occur.
[0094] A "pharmaceutical composition" refers to a mixture comprising one or more compounds according to the present disclosure or physiologically / pharmaceutical acceptable salts or prodrugs thereof, and other chemical components, such as physiologically / pharmaceutical acceptable carriers and excipients. Pharmaceutical compositions are intended to exert a biological effect by facilitating administration to an organism and promoting absorption of the active ingredients.
[0095] The term "pharmaceutical acceptable carrier" refers to any inert substance suitable for use in a formulation for delivery of an antibody or antigen-binding fragment. Carriers may be anti-adherents, adhesives, coatings, disintegrants, fillers or diluents, preservatives (such as antioxidants, antibacterial or antifungal agents), sweeteners, absorption retardants, wetting agents, emulsifiers, buffers, and the like. Examples of suitable pharmaceutical acceptable carriers include water, ethanol, polyols (glycerol, propylene glycol, and polyethylene glycol), dextrose, vegetable oils (such as olive oil), saline, buffers, buffered saline, and isotonic agents such as sucrose, polyols, sorbitol, and sodium chloride.
[0096] Further, the present disclosure includes an agent for treating a disease associated with cells positive for a target antigen (such as claudin 18.2), comprising an anti-claudin 18.2 antibody or an antibody-binding fragment thereof of the present disclosure as an active ingredient.
[0097] The claudin 18.2-related disease in the present disclosure is not particularly limited, as long as the disease is related to claudin 18.2. For example, the therapeutic response induced by the molecule of the present disclosure includes (1) blocking the binding of claudin 18.2 to its receptor / ligand by binding the molecule of the present disclosure to human claudin 18.2, or (2) killing tumor cells that overexpress claudin 18.2. Therefore, when the molecule of the present disclosure is included in a preparation and formulation suitable for therapeutic use, it is very useful for people with tumors or cancers, preferably melanoma, colon cancer, breast cancer, lung cancer, stomach cancer, intestinal cancer, kidney cancer, non-small cell lung cancer, bladder cancer, etc.
[0098] Furthermore, the present disclosure also relates to a method for immunodetection or measurement of a target antigen (e.g., claudin 18.2), a reagent for immunodetection or measurement of a target antigen (e.g., claudin 18.2), a method for immunodetection or measurement of cells expressing a target antigen (e.g., claudin 18.2), and a diagnostic agent for diagnosing a disease associated with cells positive for a target antigen (e.g., claudin 18.2), comprising as an active ingredient the antibody or antibody fragment of the present disclosure that specifically recognizes the target antigen (e.g., human claudin 18.2) and binds to the extracellular amino acid sequence or its tertiary structure.
[0099] In the present disclosure, the method for detecting or measuring the amount of a target antigen (e.g., claudin 18.2) may be any known method, including, for example, immunoassay or immunodetection methods.
[0100] Immunoassays or immunodetection methods are methods for detecting or measuring the amount of antibodies or antigens using labeled antigens or antibodies. Examples of immunoassays or immunodetection methods include radioactive immunoassays (RIA), enzyme immunoassays (EIA or ELISA), fluorescent immunoassays (FIA), luminescence immunoassays, Western blotting, and physicochemical methods.
[0101] The above diseases associated with claudin 18.2 positive cells can be diagnosed by detecting or measuring cells that express claudin 18.2 using the antibodies or antibody fragments of the present disclosure.
[0102] Cells expressing the polypeptide can be detected by known immunodetection methods, preferably immunoprecipitation, fluorescent cell staining, immunohistochemical staining, etc. Furthermore, methods such as fluorescent antibody staining using the FMAT8100HTS system (Applied Biosystem) can also be used.
[0103] In the present disclosure, the sample to be detected or measured for a target antigen (e.g., claudin 18.2), such as tissue, cell, blood, plasma, serum, pancreatic juice, urine, feces, tissue fluid, or culture medium, is not particularly limited, so long as the sample can contain cells expressing the target antigen (e.g., claudin 18.2).
[0104] Depending on the required diagnostic method, the diagnostic agent containing the monoclonal antibody or its antibody fragment of the present disclosure may also contain a reagent for carrying out an antigen-antibody reaction or a reagent for detecting an antigen-antibody reaction. The reagent for carrying out an antigen-antibody reaction includes a buffer and a salt, etc. The reagent for detection includes a reagent commonly used in an immunoassay method or an immunodetection method, such as a labeled secondary antibody that recognizes the monoclonal antibody, its antibody fragment or its conjugate, and a substrate corresponding to the label.
[0105] The details of one or more embodiments of the present disclosure are described in the specification above. Although any methods and materials similar or identical to those described herein can be used in the practice and testing of the present disclosure, the preferred methods and materials are described below. Other features, objects, and advantages of the present disclosure will become apparent throughout the specification and claims. In the specification and claims, the singular forms include the plural aspects unless the context clearly indicates otherwise. Unless expressly defined otherwise herein, all technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the disclosure belongs. All patents and publications cited herein are incorporated by reference. The following examples are provided to more fully describe the preferred embodiments of the present disclosure. These examples should not be construed in any way as limiting the scope of the present disclosure, which is defined by the claims. EXAMPLES
[0106] Example 1 Construction of cell lines overexpressing claudin 18.2 The pCDH-hClaudin18.2 lentivirus expression vector plasmid and pVSV-G, pCMV-dR8.91 lentivirus system packaging vectors were transfected into virus packaging cells 293T using Lipofectamine3000 transfection reagent. The supernatant of the medium containing the virus was collected, filtered, and centrifuged at ultra-high speed. The concentrated virus was used to infect the human gastric signet ring cell carcinoma cell line NUGC4, screened by puromycin for 2-3 weeks, and then sorted by FACS single cell sorting.
[0107] The expression level of claudin 18.2 was determined according to the tumor IHC score. Cells with claudin 18.2 expression levels equivalent to those of tumors with IHC score 3 were considered as high expressing cells, and cells with claudin 18.2 expression levels equivalent to those of tumors with IHC score 2 were considered as medium expressing cells. The expression of claudin 18.2 on the surface of lentivirus-infected NUGC4 cells was detected by FACS detection, and the NUGC4 / h-claudin 18.2 monoclonal cell line with the highest expression of claudin 18.2 was selected. At the same time, the expression of claudin 18.2 on the surface of wild-type NUGC4 cells was detected by FACS, and the NUGC4 clonal cell line with medium expression of claudin 18.2 was selected. Wild-type NUGC4 was a cell with low expression of claudin 18.2.
[0108] Selected monoclonal cell lines were expanded and cultured, frozen, and stored for subsequent assays. Claudin 18.2 sequence Genbank: NP_001002026: (SEQ ID NO: 1) MAVTACQGLGFVVSLIGIAGIIAATCMDQWSTQDLYNNPVTAVFNYQGLWRSCVRESSGFTECRGYFTLLGLPAMLQAVRALMIVGIVLGAIGLLVSIFALKCIRIGSMEDSAKANMTLTSGIMFIVSGLCAIAGVSVFANMLVTNFWMSTANMYTGMGGMVQTVQTRYTFGAALFVGWVAGGLTLIGGVMMCIACRGLAPEETNYKAVSYHASGHSVAYKPGGFKASTGFGSNTKNKKIYDGGARTEDEVQSYPSKHDYV。 Claudin 18.2 DNA sequence: (SEQ ID NO: 2) 1 AGAATTGCGC TGTCCACTTG TCGTGTGGCT CTGTGTCGAC ACTGTGCGCC ACCATGGCCG 61 TGACTGCCTG TCAGGGCTTG GGGTTCGTGG TTTCACTGAT TGGGATTGCG GGCATCATTG 121 CTGCCACCTG CATGGACCAG TGGAGCACCC AAGACTTGTA CAACAACCCC GTAACAGCTG 181 TTTTCAACTA CCAGGGGCTG TGGCGCTCCT GTGTCCGAGA GAGCTCTGGC TTCACCGAGT 241 GCCGGGGCTA CTTCACCCTG CTGGGGCTGC CAGCCATGCT GCAGGCAGTG CGAGCCCTGA 301 TGATCGTAGG CATCGTCCTG GGTGCCATTG GCCTCCTGGT ATCCATCTTT GCCCTGAAAT 361 GCATCCGCAT TGGCAGCATG GAGGACTCTG CCAAAGCCAA CATGACACTG ACCTCCGGGA 421 TCATGTTCAT TGTCTCAGGT CTTTGTGCAA TTGCTGGAGT GTCTGTGTTT GCCAACATGC 481 TGGTGACTAA CTTCTGGATG TCCACAGCTA ACATGTACAC CGGCATGGGT GGGATGGTGC 541 AGACTGTTCA GACCAGGTAC ACATTTGGTG CGGCTCTGTT CGTGGGCTGG GTCGCTGGAG 601 GCCTCACACT AATTGGGGGT GTGATGATGT GCATCGCCTG CCGGGGCCTG GCACCAGAAG 661 AAACCAACTA CAAAGCCGTT TCTTATCATG CCTCAGGCCA CAGTGTTGCC TACAAGCCTG 721 GAGGCTTCAA GGCCAGCACT GGCTTTGGGT CCAACACCAA AAACAAGAAG ATATACGATG 781 GAGGTGCCCG CACAGAGGAC GAGGTACAAT CTTATCCTTC CAAGCACGAC TATGTGTAAT 841 GCTCTAAGAC CTCTCAGCAC GGGCGGAAGA AACTCCCGGA GAGCTCACCC AAAAAACAAG 901 GAGATCCCAT CTAGATTTCT TCTTGCTTTT GACTCACAGC TGGAAGTTAG AAAAGCCTCG 961 ATTTCATCTT TGGAGAGGCC AAATGGTCTT AGCCTCAGTC TCTGTCTCTA AATATTCCAC 1021 CATAAAACAG CTGAGTTATT TATGAATTAG AGGCTATAGC TCACATTTTC AATCCTCTAT 1081 TTCTTTTTTT AAATATAACT TTCTACTCTG ATGAGAGAAT GTGGTTTTAA TCTCTCTCTC 1141 ACATTTTGAT GATTTAGACA GACTCCCCCT CTTCCTCCTA GTCAATAAAC CCATTGATGA 1201 TCTATTTCCC AGCTTATCCC CAAGAAAACT TTTGAAAGGA AAGAGTAGAC CCAAAGATGT 1261 TATTTTCTGC TGTTTGAATT TTGTCTCCCC ACCCCCAACT TGGCTAGTAA TAAACACTTA 1321 CTGAAGAAGA AGCAATAAGA GAAAGATATT TGTAATCTCT CCAGCCCATG ATTCCGGTTT 1381 TCTTACACTG TGATCTTAAA AGTTACCAAA CCAAAGTCAT TTTCAGTTTG AGGCAACCAA 1441 ACCTTTCTAC TGCTGTTGAC ATCTTCTTAT TACAGCAACA CCATTCTAGG AGTTTCCTGA 1501 GCTCTCCACT GGAGTCCTCT TTCTGTCGCG GGTCAGAAAT TGTCCCTAGA TGAATGAGAA 1561 AATTATTTTTT TTTAATTTAA GTCCTAAATA TAGTTAAAAT AAATAATGTT TTAGTAAAAT 1621 GATACACTAT CTCTGTGAAA TAGCCTCACC CCTACATGTG GATAGAAGGA AATGAAAAAA 1681 TAATTGCTTT GACATTGTCT ATATGGTACT TTGTAAAGTC ATGCTTAAGT ACAAATTCCA 1741 TGAAAAGCTC ACTGATCCTA ATTCTTTCCC TTTGAGGTCT CTATGGCTCT GATTGTACAT 1801 GATAGTAAGT GTAAGCCATG TAAAAGTAA ATAATGTCTG GGCACAGTGG CTCACGCCTG 1861 TAATCCTAGC ACTTTGGGAG GCTGAGGAGG AAGGATCACT TGAGCCCAGA AGTTCGAGAC 1921 TAGCCTGGGC AACATGGAGA AGCCCTGTCT CTACAAAATA CAGAGAGAAA AAATCAGCCA 1981 GTCATGGTGG CCTACACCTG TAGTCCCAGC ATTCCGGGAG GCTGAGGTGG GAGGATCACT 2041 TGAGCCCAGG GAGGTTGGGG CTGCAGTGAG CCATGATCAC ACCACTGCAC TCCAGCCAGG 2101 TGACATAGCG AGATCCTGTC TAAAAAAATA AAAAATAAAT AATGGAACAC AGCAAGTCCT 2161 AGGAAGTAGG TTAAAACTAA TTCTTTAAAA AAAAAAAAAA GTTGAGCCTG AATTAAATGT 2221 AATGTTTCCA AGTGACAGGT ATCCACATTT GCATGGTTAC AAGCCACTGC CAGTTAGCAG 2281 TAGCACTTTC CTGGCACTGT GGTCGGTTTT GTTTTGTTTT GCTTTGTTTA GAGACGGGGT 2341 CTCACTTTCC AGGCTGGCCT CAAACTCCTG CACTCAAGCA ATTCTTCTAC CCTGGCCTCC 2401 CAAGTAGCTG GAATTACAGG TGTGCGCCAT CACAACTAGC TGGTGGTCAG TTTTGTTACT 2461 CTGAGAGCTG TTCACTTCTC TGAATTCACC TAGAGTGGTT GGACCATCAG ATGTTTGGGC 2521 AAAACTGAAA GCTCTTTGCA ACCACACACC TTCCCTGAGC TTACATCACT GCCCTTTTGA 2581 GCAGAAAGTC TAAATTCCTT CCAAGACAGT AGAATTCCAT CCCAGTACCA AAGCCAGATA 2641 GGCCCCCTAG GAAACTGAGG TAAGAGCAGT CTCTAAAAAC TACCCACAGC AGCATTGGTG 2701 CAGGGGAACT TGGCCATTAG GTTATTATTT GAGAGGAAG TCCTCACATC AATAGTACAT 2761 ATGAAAGTGA CCTCCAAGGG GATTGGTGAA TACTCATAAG GATCTTCAGG CTGAACAGAC 2821 TATGTCTGGG GAAAGAACGG ATTATGCCCC ATTAAATAAC AAGTTGTGTT CAAGAGTCAG 2881 AGCAGTGAGC TCAGAGGCCC TTCTCACTGA GACAGCAACA TTTAAACCAA ACCAGAGGAA 2941 GTATTTGTGG AACTCACTGC CTCAGTTTGG GTAAAGGATG AGCAGACAAG TCAACTAAAG 3001 AAAAAAGAAA AGCAAGGAGG AGGGTTGAGC AATCTAGAGC ATGGAGTTTG TTAAGTGCTC 3061 TCTGGATTTG AGTTGAAGAG CATCCATTTG AGTTGAAGGC CACAGGGCAC AATGAGCTCT 3121 CCCTTCTACC ACCAGAAAGT CCCTGGTCAG GTCTCAGGTA GTGCGGTGTG GCTCAGCTGG 3181 GTTTTTAATT AGCGCATTCT CTATCCCAACA TTTAATTGTT TGAAAGCCTC CATATAGTTA 3241 GATTGTGCTT TGTAATTTTG TTGTTGTTGC TCTATCTTAT TGTATATGCA TTGAGTATTA 3301 ACCTGAATGT TTTGTTACTT AAATATTAAA AACACTGTTA TCCTACAGTT。
[0109] Example 2 Production of anti-human claudin-18.2 monoclonal antibodies 1 Immunization Anti-human claudin-18.2 monoclonal antibodies were produced by immunizing mice.
[0110] Female SJL white mice aged 6-8 weeks were used for the experiment (Beijing Vital River Laboratory Animal Technology Co., Animal Production License Number: SCXK (Beijing) 2012-0001). Feeding environment: SPF level. After purchase, the mice were kept in the experimental environment for 1 week at a temperature of 20-25 °C, humidity of 40-60%, and a 12 / 12 hour light / dark cycle. The mice that had adapted to the environment were then immunized according to the following scheme. The immunization antigen was hu claudin18.2-HEK293 cells (HEK-293 cell line stably transfected with human claudin18.2 plasmid).
[0111] Immunization protocol: Prior to primary immunization with cells, mice were injected intraperitoneally (IP) with TiterMax® Gold Adjuvant (Sigma, Cat. No. T2684) at 0.1 ml / mouse; 30 minutes later, each mouse was immunized with 1×10 8 The cell suspension diluted to a concentration of 1 × 10 / ml was injected intraperitoneally (IP). After uniformly dispersing the cells by pipetting, the cells were inoculated on days 0, 14, 28, 42, and 56. Blood samples were collected on days 21, 35, 49, and 63; the antibody titers in the mouse serum were determined by ELISA. After 4-5 immunizations, mice with high serum antibody titers that reached a plateau were selected for fusion with splenocytes. Three days before fusion with splenocytes, 1 × 10 cells were injected for booster immunization. 7 The cells were injected intraperitoneally (IP).
[0112] 2. Fusion with splenocytes Hybridoma cells were obtained by fusing splenic lymphocytes with myeloma Sp2 / 0 cells (ATCC® CRL-8287™) using a PEG-mediated fusion procedure. Hybridoma cells were cultured at 0.5×10 6 ~1×10 6 The cells were resuspended in complete medium (IMDM medium containing 20% FBS, 1x HAT, 1x OPI) at a density of 100 μl / well and seeded into a 96-well plate at 100 μl / well, incubated at 37°C and 5% CO2 for 3-4 days, and then maintained for another 3-4 days until clones were formed after adding 100 μl / well of HAT complete medium. The supernatant was removed, and 200 μl / well of HT complete medium (IMDM medium containing 20% FBS, 1x HT, and 1x OPI) was added, incubated at 37°C and 5% CO2 for 3 days, and then subjected to ELISA detection.
[0113] 3. Screening of Hybridoma Cells Depending on the proliferation density of hybridoma cells, the culture supernatant was detected by binding ELISA method. After selecting cells that had strong binding ability to hu claudin18.2-HEK293 cells but not to HEK293 cells, they were expanded promptly and cryopreserved; subcloning was performed 2-3 times until a single cell clone was obtained.
[0114] The cells after each subcloning were also tested by cell binding assay. Hybridoma clones were obtained by screening with the above assay. Antibodies were further prepared by serum-free cell culture method. The antibodies were purified according to the purification example and used in the test example.
[0115] Example 3 Humanization of mouse antibodies Monoclonal hybridoma cell lines mAb1901 and mAb1902 with high in vitro activity were selected; the monoclonal antibody sequences were cloned, humanized, recombinantly expressed, and evaluated for activity.
[0116] The procedure for cloning sequences from hybridomas was as follows: Hybridoma cells in logarithmic growth phase were harvested. RNA was extracted by Trizol (Invitrogen, 15596-018) and reverse transcribed by PrimeScript™ reverse transcriptase (Takara, Cat. No. 2680A) according to the kit's instruction manual. The cDNA obtained from the reverse transcription was amplified by PCR using Mouse Ig-Primer Set (Novagen, TB326 Rev.B0503), and the amplified products were sent to a company for sequencing. The amino acid sequences corresponding to the obtained DNA sequences are shown in SEQ ID NOs: 3-6. mAb1901 Mouse Heavy Chain Variable Region (SEQ ID NO:3) EVQLMESGGGLVKPGGSLKLSCAASGFTFSDYGIHWVRQAPEMGLEWIAYISRGSSTIYYADTVKGRFTMSRDNAKNTLFLQMTSLRSEDTAMYYCARGGYDTRNAMDYWGQGTSVTVSS. mAb1901 Mouse Light Chain Variable Region (SEQ ID NO:4) DIVMTQSPSSLSVSAGEKVTMSCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRASGVPDRFTGSGSGTDFTLTISSVQAEDLAIYHCQNDLYYPLTFGAGTKLELK. mAb1902 Mouse Heavy Chain Variable Region (SEQ ID NO:5) EVQLQESGAELVKPGASVKLSCKASGYIFTSYWMHWVKQRPGQGLEWIGMIHPNSGSTNYNEKFKGKATLTLDKSSSTAYMQLSSLPSEDSAVYYCARLKTGNSFDYWGQGTTLTVSS. mAb1902 Mouse Light Chain Variable Region (SEQ ID NO:6) DIVLTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAIYYCQNAYTYPFTFGSGTKLEIK.
[0117] The mouse heavy and light chain variable regions were linked to the human IgG1 heavy chain constant region and human kappa light chain constant region, respectively, to form the chimeric antibodies ch1901 and ch1902.
[0118] The constant regions were selected from the following sequences: Human IgG1 antibody heavy chain constant region (SEQ ID NO:7) ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK. Human kappa light chain constant region: (SEQ ID NO:8) RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.
[0119] Mouse monoclonal antibodies were humanized as disclosed in many documents in the art. Briefly, the parent (mouse antibody) constant domain was replaced by a human constant domain, and based on the homology between mouse and human antibodies, human germline antibody sequences were selected to perform CDR grafting. In the present invention, candidate molecules with favorable activities were selected for humanization, and the results are as follows:
[0120] 1. Mouse antibody CDR region The VH / VL CDR amino acid residues in Table 4 are determined and annotated according to the Kabat numbering system. The CDR sequences of the murine antibodies are shown in Table 4.
[0121] [Table 4]
[0122] 2. Selection of human germline FR region sequences Based on the obtained mouse antibody VH / VLCDR typical structure, the heavy and light chain variable region sequences were compared with the antibody germline database to obtain highly homologous human germline templates. The human germline light chain framework regions were derived from the human kappa light chain gene.
[0123] 2.1 Design of humanization and backmutation of mAb1901 A suitable human antibody germline for humanization of the mAb1901 mouse antibody was selected. The CDR regions of the mouse antibody mAb1901 were grafted into the selected humanization template to obtain the humanized variable regions. The humanized heavy chain variable region sequence shown in SEQ ID NO:24 and the light chain variable region sequence shown in SEQ ID NO:21 were combined with an IgG constant region to form an intact antibody. At the same time, the FR regions in the V regions of the humanized antibody were backmutated, with exemplary backmutations and combinations as follows:
[0124] [Table 5] * All amino acid positions in the table are numbered according to the Kabat numbering standard. In the case of N82T in the heavy chain variable region, 82 refers to position 82A according to the Kabat standard.
[0125] [Table 6]
[0126] The corresponding heavy chain variable regions shown in the table above can be linked to the human IgG1 heavy chain constant region shown in SEQ ID NO:7 to form the heavy chain of a full-length antibody, and the light chain variable regions can be linked to the human kappa light chain constant region shown in SEQ ID NO:8 to form the light chain of a full-length antibody. In other embodiments, the heavy and light chain variable regions can be linked separately to other heavy and light chain constant regions to form full-length antibodies.
[0127] 2.2 Humanization and backmutation design of mAb1902 A suitable human antibody germline for humanization of mAb1902 mouse antibody was selected. The CDR regions of mouse antibody mAb1902 were grafted into the selected humanization template to obtain a humanized variable region. The humanized heavy chain variable region sequence is as shown in SEQ ID NO:31, and the light chain variable region sequence is as shown in SEQ ID NO:28; then recombined with IgG constant region to form an intact antibody. At the same time, the FR regions in the V region of the humanized antibody were backmutated, and the exemplary backmutation methods and combinations are as follows:
[0128] [Table 7]
[0129] [Table 8]
[0130] The corresponding heavy chain variable regions shown in the table above can be linked to the human IgG1 heavy chain constant region shown in SEQ ID NO:7 to form a full-length antibody heavy chain, and the light chain variable regions can be linked to the human kappa light chain constant region shown in SEQ ID NO:8 to form a full-length antibody light chain.
[0131] As an example, the full length sequence of an antibody is as follows: Chimeric antibody ch1901: ch1901 heavy chain: (SEQ ID NO:35) EVQLMESGGGLVKPGGSLKLSCAASGFTFSDYGIHWVRQAPEMGLEWIAYISRGSSTIYYADTVKGRFTMSRDNAKNTLFLQMTSLRSEDTAMYYCARGGYDTRNAMDYWGQ GTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK; ch1901 light chain (SEQ ID NO:36) DIVMTQSPSSLSVSAGEKVTMSCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRASGVPDRFTGSGSGTDFTLTISSVQAEDLAIYHCQNDLYYPLTFGAGTKL ELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC; Chimeric antibody ch1902: ch1902 heavy chain (SEQ ID NO:37) EVQLQESGAELVKPGASVKLSCKASGYIFTSYWMHWVKQRPGQGLEWIGMIHPNSGSTNYNEKFKGKATLTLDKSSSTAYMQLSSLPSEDSAVYYCARLKTGNSFDYWGQGT TLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK; ch1902 light chain (SEQ ID NO:38) DIVLTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAIYYCQNAYTYPFTFGSGTKL EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.
[0132] [Table 9]
[0133] The light and heavy chain sequences of the full length antibody are as follows:
[0134] [Table 10-1] [Table 10-2] [Table 10-3]
[0135] [Table 11]
[0136] The light and heavy chain sequences of the full length antibody are as follows:
[0137] [Table 12-1]
[0138] The positive control antibody of the present disclosure was IMAB-362 (available from WO2016166122). IMAB-362 heavy chain (SEQ ID NO:53) 1 QVQLQQPGAE LVRPGASVKL SCKASGYTFT SYWINWVKQR PGQGLEWIGN 51 IYPSDSYTNY NQKFKDKATL TVDKSSSTAY MQLSSPTSED SAVYYCTRSW 101 RGNSFDYWGQ GTTLTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 151 FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 201 CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 251 TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 301 YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 351 TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 401 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK. IMAB-362 light chain (SEQ ID NO:54) 1 DIVMTQSPSS LTVTAGEKVT MSCKSSQSLL NSGNQKNYLT WYQQKPGQPP 51 KLLIYWASTR ESGVPDRFTG SGSGTDFTLT ISSVQAEDLA VYYCQNDYSY 101 PFTFGSGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 151 KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 201 EVTHQGLSSP VTKSFNRGEC.
[0139] The antibodies were cloned, expressed and purified by conventional gene cloning and recombinant expression methods.
[0140] In vitro biological evaluation Test Example 1: ELISA binding assay at the cell level A cell-based ELISA assay was used to detect the binding properties of claudin 18.2 antibodies. NUGC4 cells stably expressing claudin 18.2 were cultured in 96-well cell plates (Corning, 3599) until the cell proliferation density reached 90%, and 4% paraformaldehyde was added to fix the cells for 1 h. After washing the plate three times with PBST buffer (PBS, pH 7.4 containing 0.05% Tween-20), the plate was blocked by adding 200 μl / well of 5% skim milk (Bright nonfat dry milk) diluted in PBS as a blocking solution, and incubated for 2.5 h in a 37°C incubator or overnight (16-18 h) at 4°C. After blocking, the blocking solution was discarded, the plate was washed three times with PBST buffer, and 50 μl / well of the test antibody diluted in sample diluent (PBS, pH 7.4 containing 1% skim milk) was added and incubated at 37°C for 2 h. After the incubation was completed, the plate was washed five times with PBST, and 100 μl / well of HRP-conjugated goat anti-human secondary antibody (Jackson Immuno Research, Cat. No. 109-035-003) diluted in sample diluent was added and incubated at 37°C for 1 hour. After washing the plate six times with PBST, 50 μl / well of TMB chromogenic substrate (KPL, Cat. No. 52-00-03) was added, incubated at room temperature for 10-15 minutes, and 50 μl / well of 1M H2SO4 was added to stop the reaction. The absorbance values were read at 450 nm by a MD Versa Max™ microplate reader, and the EC50 values, which indicate the claudin 18.2 antibody bound to claudin 18.2, were calculated (the results are shown in the table below).
[0141] [Table 13]
[0142] [Table 14-1]
[0143] [Table 14-2]
[0144] Test Example 2: Antibody binding assay at the cellular level NUGC4 cells stably expressing claudin 18.2 were cultured at 1 × 10 cells / well with FACS buffer (2% fetal bovine serum (Gibco, 10099141) in PBS (Sigma, P4417-100 tab), pH 7.4). 6 A cell suspension of 100 μl / ml was prepared and added to a 96-well round-bottom plate (Corning, 3795) at 100 μl / well. After centrifugation and removal of the supernatant, various concentrations of test claudin 18.2 antibodies diluted in FACS buffer were added at 50 μl / well and incubated for 1 h in the dark in a 4°C refrigerator. After centrifugation at 300 g and washing three times with FACS buffer, a working concentration of anti-human IgG (H+L) coated with Alexa Fluor488 (invitrogen, A-11013) was added and incubated for 40 min in the dark in a 4°C refrigerator. After centrifugation at 300 g and washing three times with FACS buffer, the geometric mean fluorescence intensity was measured by a BD FACS CantoII flow cytometer and the EC50 value was calculated, which indicates the claudin 18.2 antibody binding to NUGC4 cells stably expressing claudin 18.2. The results are shown in Figure 1.
[0145] Test Example 3: Antibody endocytosis assay Test claudin 18.2 antibodies pre-labeled with DyLight488 NHS ester (thermofisher, 46403) were added to 1 × 10 cells stably expressing claudin 18.2 at a final concentration of 5 μg / ml. 61000g / ml of NUGC4 cells, placed on ice, incubated in the dark for 1 hour, centrifuged, washed three times with pre-cooled FACS buffer (2% fetal bovine serum in PBS, pH 7.4), the supernatant was removed, pre-warmed complete medium was added, and placed in a cell incubator at 37°C and 5% CO2. After 0, 0.5, 1, 2, and 4 hours, the cells were removed and placed on ice in the dark. All samples were collected and centrifuged at 300g in the cold, followed by addition of elution buffer (0.05M glycine, 0.1M sodium chloride, pH 1.7) and incubation at room temperature for 7 minutes. The samples were centrifuged at 300g, washed once with FACS buffer, and the geometric mean fluorescence intensity was measured by a BD FACS CantoII flow cytometer to calculate the endocytosis efficiency of claudin18.2 antibody against NUGC4 cells stably expressing claudin18.2. The results (see FIG. 2) show that the humanized antibody has favorable endocytosis efficiency.
[0146] Test Example 4: Measurement of antibody affinity based on flow cytometry On the day of the test, 1 x 10 per well 5 ~2×10 5HEK293 / hClaudin18.2 cells were harvested and placed into a round-bottom 96-well plate so that each cell was 100 μg / ml. Claudin18.2 antibody was added at an initial concentration of 5 μg / ml, 2-fold gradient dilution (12 concentration points), and incubated at 4°C for 1 hour. The positive control was IMAB362, and wells without antibody were set as negative controls. After removing the antibody by centrifugation, 100 μl / well of FITC anti-human IgG Fc antibody (200×) was added, incubated at 4°C for 30 minutes in the dark, washed twice with PBS+2%FBS, and prepared for flow cytometry detection. The BD FACS CantoII was started and preheated, and a new assay was established by BD FACS Diva software. The HEK293 / hClaudin18.2 negative control sample was detected, and the FSC and SSC voltages were adjusted to appropriate values and stored. Blank sample B and standard curve 1 were detected according to the instruction manual of Quantum FITC-5 MESF kit, respectively. The FITC voltage was adjusted to an appropriate value and saved. Under the saved voltage, the samples in the round-bottom 96-well plate were detected and the data was recorded. Flowjo software was used to analyze the experimental data, whereby the Geo Mean value was obtained, and the MESF-Geo Mean standard curve was fitted according to the instruction manual of Quantum FITC-5 MESF kit. The molar concentration of claudin 18.2 antibody bound to HEK293 / h claudin 18.2 cells and the concentration of free antibody were calculated based on the concentration fluorescence value of FITC anti-human IgG Fc antibody, and the Bmax and dissociation constant KD of the antibody were calculated by using the Scatchard plot method. The results are shown in Table 15.
[0147] [Table 15]
[0148] Test Example 5: Evaluation of ADCC effect of antibodies Various NUGC4 cells (high, medium and low expression of claudin 18.2) were digested, centrifuged at 1000 rpm, resuspended and counted. Cells were cultured at 3 × 10 in phenol red-free RPMI 1640 (Gibco, Cat. No. 11835-030) containing 10% FBS (Ultra-low IgG fetal bovine serum from New Zealand, Gibco, 1921005PJ). 5 The cells were resuspended at 7500 cells / ml. 25 μl of cells were added to each well of a 96-well plate (Corning, 3903) at 7500 cells / well. Antibodies were diluted in the above phenol red-free medium to prepare 3-fold antibody dilutions, and 25 μl / well of antibody was added to the cell plate and incubated for 0.5 hours in a 37°C 5% CO2 incubator.
[0149] (FcrR3A-V158-NFAT-RE-Jurkat cells) Effector cells were collected, centrifuged at 1000 rpm, resuspended and counted. Cells were cultured at 3 × 10 in phenol red-free RPMI 1640 containing 10% FBS (Ultra-low IgG fetal bovine serum from New Zealand). 6 Resuspend cells at 7.5 x 10 cells / ml and add 25 μl of cells to the assay plate (7.5 x 10 4 cells / well) and incubated at 37°C in a 5% CO2 incubator for 6 hours.
[0150] 75 μl / well of Bright-Glo (Promega, E2610) was added to each well of the assay plate, and chemiluminescence was detected by a microplate reader (PerkinElmer, VITOR3).
[0151] The results (see Table 16 and Figures 3A-3C) show that both antibodies h1901-11 and h1902-5 exhibited very strong ADCC activity in NUGC4 cells that expressed low, medium and high levels of claudin 18.2.
[0152] [Table 16]
Claims
1. An anti-claudin 18.2 antibody comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as set forth in SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, respectively; Anti-claudin 18.2 antibody.
2. The anti-claudin 18.2 antibody of claim 1, which is a mouse antibody, a chimeric antibody or a humanized antibody.
3. The anti-claudin 18.2 antibody of claim 1 or 2, comprising a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is as set forth in SEQ ID NO:5 or has at least 90% identity to SEQ ID NO:5, and the amino acid sequence of the light chain variable region is as set forth in SEQ ID NO:6 or has at least 90% identity to SEQ ID NO:6; or the amino acid sequence of the heavy chain variable region is as set forth in SEQ ID NO:31 or has at least 90% identity to SEQ ID NO:31, and the amino acid sequence of the light chain variable region is as set forth in SEQ ID NO:28 or has at least 90% identity to SEQ ID NO:28; Anti-claudin 18.2 antibody.
4. The anti-claudin 18.2 antibody of claim 3, which is a humanized antibody comprising a framework region derived from a human antibody or a variant of the framework region, wherein the variant of the framework region has 1 to 10 back mutations in the light chain framework region and / or the heavy chain framework region of the human antibody.
5. The anti-claudin 18.2 antibody according to claim 4, The framework region variants include one or more back mutations selected from the group consisting of 4L and 22S in the light chain variable region, and / or one or more back mutations selected from the group consisting of 38K, 40R, 48I, 66K, 67A, 69L, 71L, and 73K in the heavy chain variable region. Anti-claudin 18.2 antibody.
6. The heavy and light chain variable regions are shown below: A heavy chain variable region sequence shown in SEQ ID NO:5 and a light chain variable region sequence shown in SEQ ID NO:6; or A heavy chain variable region sequence shown in SEQ ID NO: 31, 32, 33 or 34 and a light chain variable region sequence shown in SEQ ID NO: 28, 29 or 30 The anti-claudin 18.2 antibody of claim 5 .
7. The anti-claudin 18.2 antibody according to claim 6, The anti-claudin 18.2 antibody or antigen-binding fragment thereof has a heavy chain variable region and a light chain variable region as shown below: The heavy chain variable region sequence shown in SEQ ID NO: 31 and the light chain variable region sequence shown in SEQ ID NO: 29 An anti-claudin 18.2 antibody comprising:
8. The anti-claudin 18.2 antibody of any one of claims 1 to 7, further comprising a heavy chain constant region and a light chain constant region, the heavy chain constant region is selected from the group consisting of human IgG1, IgG2, IgG3, and IgG4 constant regions and variants thereof; The light chain constant region is selected from the group consisting of human antibody κ and λ chain constant regions and variants thereof. Anti-claudin 18.2 antibody.
9. The anti-claudin 18.2 antibody according to claim 8, The anti-claudin 18.2 antibody comprises a heavy chain constant region shown in SEQ ID NO: 7 and a light chain constant region shown in SEQ ID NO:
8. Anti-claudin 18.2 antibody.
10. A heavy chain as set forth in SEQ ID NO:37 and a light chain as set forth in SEQ ID NO:38; or A heavy chain shown in SEQ ID NO: 49, 50, 51 or 52 and a light chain shown in SEQ ID NO: 46, 47 or 48 The anti-claudin 18.2 antibody of any one of claims 1 to 9, comprising:
11. Heavy chain shown in SEQ ID NO:49 and light chain shown in SEQ ID NO:47 The anti-claudin 18.2 antibody of any one of claims 1 to 10, comprising:
12. A nucleic acid molecule encoding an anti-claudin 18.2 antibody according to any one of claims 1 to 11.
13. A host cell comprising the nucleic acid molecule of claim 12.
14. An antibody-drug conjugate formed by conjugating an anti-claudin 18.2 antibody of any one of claims 1 to 11 to a cytotoxic drug.
15. A pharmaceutical composition comprising a therapeutically effective amount of an anti-claudin 18.2 antibody described in any one of claims 1 to 11 or an antibody-drug conjugate described in claim 14, and one or more pharma- ceutically acceptable carriers, diluents, buffers or excipients.
16. Contacting the anti-claudin 18.2 antibody according to any one of claims 1 to 11 with a sample to be tested. A method for immunoassay or detection of claudin 18.2 comprising:
17. A kit comprising an anti-claudin 18.2 antibody according to any one of claims 1 to 11.
18. 16. The pharmaceutical composition according to claim 15 for the treatment of a disease associated with claudin 18.2, wherein the disease is a tumor.
19. 19. The pharmaceutical composition of claim 18, wherein the disease is selected from the group consisting of head and neck squamous cell carcinoma, head and neck cancer, brain cancer, glioma, glioblastoma multiforme, neuroblastoma, central nervous system cancer, neuroendocrine tumor, pharyngeal cancer, nasopharyngeal cancer, esophageal cancer, thyroid cancer, malignant pleural mesothelioma, lung cancer, breast cancer, liver cancer, hepatocellular tumor, hepatocellular carcinoma, hepatobiliary cancer, pancreatic cancer, gastric cancer, gastrointestinal cancer, intestinal cancer, colon cancer, colorectal cancer, kidney cancer, clear cell renal cell carcinoma, ovarian cancer, endometrial cancer, cervical cancer, bladder cancer, prostate cancer, testicular cancer, skin cancer, melanoma, leukemia, lymphoma, bone cancer, chondrosarcoma, myeloma, multiple myeloma, myelodysplastic syndrome, Krukenberg's tumor, myeloproliferative neoplasm, squamous cell carcinoma, Ewing's sarcoma, systemic light chain amyloidosis, and Merkel cell carcinoma.
20. the lymphoma is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, primary mediastinal large B-cell lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, T-cell / histiocyte-rich large B-cell lymphoma, and lymphoplasmacytic lymphoma; the lung cancer is selected from the group consisting of non-small cell lung cancer and small cell lung cancer; The leukemia is selected from the group consisting of chronic myeloid leukemia, acute myeloid leukemia, lymphocytic leukemia, lymphoblastic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and myeloid leukemia.
20. The pharmaceutical composition of claim 19.
Citation Information
Patent Citations
Monoclonal antibody against claudin 18 for cancer treatment
JP2010528075A
Antibodies against claudin 18.2, which are useful for cancer diagnosis.
JP2015517476A
Drug conjugates containing antibodies against claudin 18.2
JP2018513146A
Antibody for Anti-claudin 18a2 and use thereof
WO2018006882A1
